Ali Mobasheri is currently Professor of Musculoskeletal Physiology in the School of Veterinary Medicine at the University of Surrey. He received his BSc (Hons) in Biochemistry from Imperial College London in 1990. He then took up an Open Fellowship at the University of Toronto in Canada and completed a three-year Master's degree in Physiology and Biochemistry. In 1993 he returned to the UK to work on his Doctorate in Molecular and Cellular Physiology funded by the Arthritis and Rheumatism Council (now known as Arthritis Research UK). He was affiliated with Wolfson College Oxford and received his D.Phil. from the University of Oxford in 1997. Shortly after completing his D.Phil. he worked in Edinburgh as a Post-Doc and then in London and Liverpool as Lecturer (1997-2005) and then as Senior Lecturer (2005-2006) at the University of Liverpool. In 2006 he was promoted to Associate Professor and Reader at the University of Nottingham. In February 2013 he was appointed as a Visiting Adjunct Professor in the Distinguished Scientist Program of King AbdulAziz University, Kingdom of Saudi Arabia. In April 2014 Ali joined the University of Surrey as a full professor and was appointed Associate Dean (Research & Enterprise) in August 2015. He held this role until the end of January 2017. Ali’s research focuses on cartilage biology and biomarkers of osteoarthritis. He currently co-ordinates the EU FP7 funded D-BOARD consortium, which brings together leading European academic institutions and SMEs to focus on the identification, validation and qualification of new biomarkers for degenerative and inflammatory diseases of joints. He is also a member of the APPROACH Consortium and has received funding from the Innovative Medicines Initiative (IMI), a joint undertaking between the European Union (EU) and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Ali is a member of the Board of Directors of the Osteoarthritis Research Society International (OARSI) and chairs the OARSI Strategic Alliance Committee until April 2017, when he will become President-Elect of OARSI. He also serves on the Scientific, Ethics and Advisory Board (SEAB) of the FP7 SYBIL (Systems biology for the functional validation of genetic determinants of skeletal diseases) consortium. He has published 207 peer-reviewed papers and his current h-index on Scopus is 43.